Q-omics provides the consensus-scored MIR3128 profile across patient tissues and cancer cell-line models. MIR3128 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR3128 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, MIR3128 RNA expression shows 10,044 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BRCA, and THYM as cancer lineages where MIR3128 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3128 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3128 survival associations across molecular data types. MIR3128 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3128 RNA expression–survival associations across cancer types. High MIR3128 expression shows unfavorable associations in KIRC, UCS, COAD, UCEC, THCA and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR3128 RNA expression.
This table summarizes MIR3128 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3128. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3128 shows lower tumor expression in BRCA, THCA and KIRC and higher tumor expression in HNSC and LUSC. The BRCA box plot shows higher MIR3128 RNA expression in normal versus tumor tissue (log2 FC = −1.145, t-test p < 0.001).
This table shows molecular features associated with MIR3128 in patient tissues and cancer cell lines. In patient samples, MIR3128 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
